Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients

Infection

Volumn 37, Issue 3, 2009, Pages 233-243

  Santoro, M M ^a   Bertoli, A ^b   Lorenzini, P ^c   Ceccherini Silberstein, F ^a   Gianotti, N ^d   Mussini, C ^e   Torti, C ^f   Di Perri, G ^g   Barbarini, G ^h   Bini, T ⁱ   Melzi, S ⁱ   Caramello, P ^j   Maserati, R ^h   Narciso, P ^c   Micheli, V ⁱ   Antinori, A ^c   Perno, C F ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h IRCCS   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j AMEDEO DI SAVOIA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; RITONAVIR;

ADJUVANT THERAPY; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; PREDICTION; PRESCRIPTION; VIRUS MUTATION; AMINO ACID SEQUENCE; CHI SQUARE DISTRIBUTION; CODON; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; LONGITUDINAL STUDY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; MUTATION; PROSPECTIVE STUDY; STATISTICAL MODEL; TREATMENT OUTCOME; VIREMIA; VIROLOGY; VIRUS LOAD;

AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; CODON; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; MUTATION; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PYRIDINES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 67650224695     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-8065-4     Document Type: Article

References (38)

1. DHHS panel on antiretroviral guidelines for adults and adolescents: guidelines for the use of antiretroviral agents in HIV-1- Infected adults and adolescents 2007. Available at: http://aidsinfo.nih.gov/Guidelines/.
2. Euro Guidelines Group for HIV Resistance 2001 Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting AIDS 15 309 320
3. M.S. Hirsch F. Brun-Vezinet B. Clotet 2003 Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003. Recommendations of an international AIDS society-USA panel Clin Infect Dis 37 113 128
4. F. Brun-Vezinet D. Descamps A. Ruffault 2003 Clinically relevant interpretation of genotype for resistance to abacavir AIDS 17 1795 1802
5. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3 (Abstract 73). XV International HIV Drug Resistance Workshop. Sitges, June 2006.
6. M.S. King R. Rode I. Cohen-Codar 2007 Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients Antimicrob Agents Chemother 51 3067 3074
7. A.G. Marcelin C. Lamotte C. Delaugerre 2003 Genotypic inhibitory quotient as predictor of virological response to ritonaviramprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients Antimicrob Agents Chemother 47 594 600
8. A.G. Marcelin C. Dalban G. Peytavin 2004 Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients Antimicrob Agents Chemother 48 4687 4692
9. A.G. Marcelin P. Flandre J. Pavie 2005 Clinically relevant genotype interpretation of resistance to didanosine Antimicrob Agents Chemother 49 1739 1744
10. A.G. Marcelin P. Flandre C. de Mendoza 2007 Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor- experienced patients Antivir Ther 12 247 252
11. B. Masquelier D. Breilh D. Neau 2002 Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients Antimicrob Agents Chemother 46 2926 2932
12. Masquelier B, Assoumou KL, Descamps D, et al. Genotypic determinants of the virological response to fosamprenavir/ritonavir in protease inhibitors experienced patients (Abstract 91). XV International HIV Drug Resistance Workshop. Sitges, June 2006.
13. I. Pellegrin D. Breilh J.M. de Ragnaud 2006 Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study) Antivir Ther 11 421 429
14. L. Valer D. de Gonzalez Requenade C. Mendoza 2004 Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens AIDS Patient Care STDS 18 1 6
15. L. Valer C. de Mendoza V. Soriano 2005 Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experiencedHIVinfected patients J Med Virol 77 460 464
16. S. Vora A.G. Marcelin H.F. Günthard 2006 Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor- experienced patients AIDS 20 35 40
17. J.D. Baxter J.M. Schapiro C.A. Boucher 2006 Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir J Virol 80 10794 10801
18. Descamps D, Lambert-Niclot S, Marcelin AG, et al. Mutations associated with virologic response to darunavir/ritonavir in HIV-1-infected PI-experienced patients [PS 4/3]. 11th European AIDS Conference. Madrid, October 2007.
19. Scherer J, Boucher CA, Baxter JD, Schapiro JM, Kohlbrenner VM, Hall DB: Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score (poster 3.4/07). 11th European AIDS Conference. Madrid, October 2007.
20. B. Gazzard 2006 BHIVA Writing Committee: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) HIV Med 7 487 503
21. D.R. Goldsmith C.M. Perry 2003 Atazanavir Drugs 63 1679 1673
22. D.V. Havlir S.D. O'Marro 2004 Atazanavir: new option for treatment of HIV infection Clin Infect Dis 38 1599 1604
23. P. Flandre A.G. Marcelin J. Pavie 2005 Comparison of tests and procedures to build clinically relevant genotypic scores: application to the JAGUAR study Antivir Ther 10 479 487
24. V.A. Johnson F. Brun-Vézinet B. Clotet 2005 Update of the drug resistance mutations in HIV-1: fall 2005 Top HIV Med 13 125 131
25. Stanford University: HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu. Accessed August 2007.
26. F. Brun-Vézinet D. Costagliola M.A. Khaled 2004 Clinically validated genotype analysis: guiding principles and statistical concerns Antivir Ther 9 465 478
27. M.M. Santoro A. Bertoli P. Lorenzini 2008 Viro-immunological response to ritonavir boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study AIDS Patient Care STDS 22 7 16
28. Gonzalez de Requena D, Bonora S, Cavecchia I, et al. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: definition of therapeutic range [Abstract 60]. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, April 2005.
29. Elston R, Randall S, Xu F, et al. High plasma trough levels favour the selection of the I50V mutation pathway during development of APV resistance (Abstract 5.1). 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, April 2001.
30. Elston R, Randall S, Myers R, et al. Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance (Abstract 465). VIII Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001.
31. A.M. Taburet C. Piketty C. Chazallon 2004 Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-Infected patients Antimicrob Agents Chemother 48 2091 2096
32. M. Johnson B. Grinsztejn C. Rodriguez 2006 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures AIDS 20 711 718
33. L.K. Naeger K.A. Struble 2006 Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients AIDS 20 847 853
34. M. Johnson B. Grinsztejn C. Rodriguez 2005 Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures AIDS 19 685 694
35. R.J. Colonno A. Thiry K. Limoli N. Parkin 2003 Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors Antimicrob Agents Chemother 47 1324 1333
36. N. Gianotti E. Seminari M. Guffanti 2005 Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir New Microbiol 28 119 125
37. V. Svicher F. Ceccherini-Silberstein F. Erba 2005 Characterization of novel HIV-1 protease mutations potentially involved in resistance to protease inhibitors Antimicrob Agents Chemother 49 2015 2025
38. Flandre P, Marcelin AG, Soriano V, Yerly S, Katlama C, Calvez V: A method to estimate the weights for mutations within genotypic resistance scores: application to atazanavir and saquinavir (Abstract 167). XV International HIV Drug Resistance Workshop. Sitges, June 2006.